Lansoprazole Preventing Gastroduodenal Stress Ulcerations
Stopped early · Phase 4
Conditions studied: Patients Undergoing Elective Coronary Artery Bypass Graft
In brief
The primary objective of this study is to determine whether lansoprazole, administered intravenously, can protect patients undergoing cardiac surgery from the development of and/or progression of previously undetected acid/peptic disorders (erosive esophagitis, gastric ulcer, duodenal ulcer, diffuse gastritis, duodenitis) as measured by the Lanza score and LA classification for esophageal injury. The secondary objectives of this study are: 1. To determine if intravenous lansoprazole protects against the development of clinically important gastrointestinal bleeding in this population (overt bleeding or requiring blood transfusion). 2. To determine if intravenous lansoprazole maintains the intragastric pH above that for placebo throughout the study period.
Key facts
- Study ID
- NCT00220909
- Run by
- Temple University
- People needed
- 40
- Starts
- 2005-09-01
- Expected to finish
- 2006-01-01
- Last updated by the study team
- 2008-01-11
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients undergoing cardiovascular surgery, specifically elective coronary artery bypass graft or cardiac valve replacement surgery, at Temple University Hospital
- Able to provide informed consent
You may not qualify if…
- Evidence of active gastrointestinal bleeding
- Prior gastric (e.g. Billroth II) or esophageal surgery
- Pregnancy
- Pre-existing or current condition requiring acid-suppressive therapy - e.g. reflux esophagitis, gastric or duodenal ulcer
- Current use of acid-suppressive therapy, such as proton pump inhibitors or histamine type 2 receptor antagonists
- Contraindication to naso- or oro-gastric intubation (e.g. Zenker's diverticulum, esophageal stricture)
- Bleeding diathesis
- Allergy to lansoprazole
- Advanced renal disease (BUN>40 and/or creatinine>2.0.
- Advanced liver disease (Alkaline phosphatase, ALT, AST>2 x normal)
Where it is running
- Temple University School of Medicine — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.